HCW Biologics Inc. (HCWB) stock
HCWBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/3095% below fair value
$0.76−0.01 (-1.65%)
Close on Nov 18, 2026Market cap $1.40MP/E –Yield –
HCW Biologics operating margin
Operating margin is operating income as a percentage of revenue.
HCW Biologics's operating margin for the twelve months ending Jun 30, 2026 was -115.3%. For fiscal 2025 it was -24270.7%, against -1147.6% the year before. The highest annual figure on record is -142.1% in fiscal 2020.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -24270.7% | −23123.1 |
| FY2024 | Dec 31, 2024 | -1147.6% | −242.6 |
| FY2023 | Dec 31, 2023 | -905.0% | −680.6 |
| FY2022 | Dec 31, 2022 | -224.3% | −82.2 |
| FY2020 | Dec 31, 2020 | -142.1% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -2601.1% | +50285.6 |
| Q1 FY2026 | Mar 31, 2026 | 49.8% | +38861.3 |
| Q4 FY2025 | Dec 31, 2025 | -16519.1% | −15721.9 |
| Q3 FY2025 | Sep 30, 2025 | -21095.3% | −20231.2 |
| Q2 FY2025 | Jun 30, 2025 | -52886.7% | −50440.9 |
| Q1 FY2025 | Mar 31, 2025 | -38811.5% | −38146.4 |
| Q4 FY2024 | Dec 31, 2024 | -797.2% | +16.1 |
| Q3 FY2024 | Sep 30, 2024 | -864.1% | −268.8 |
| Q2 FY2024 | Jun 30, 2024 | -2445.8% | −1721.6 |
| Q1 FY2024 | Mar 31, 2024 | -665.1% | +12133.8 |
| Q4 FY2023 | Dec 31, 2023 | -813.3% | −390.9 |
| Q3 FY2023 | Sep 30, 2023 | -595.2% | −373.0 |
| Q2 FY2023 | Jun 30, 2023 | -724.2% | +49.1 |
| Q1 FY2023 | Mar 31, 2023 | -12798.9% | −12738.6 |
| Q4 FY2022 | Dec 31, 2022 | -422.4% | −472.7 |
| Q3 FY2022 | Sep 30, 2022 | -222.2% | – |
| Q2 FY2022 | Jun 30, 2022 | -773.4% | – |
| Q1 FY2022 | Mar 31, 2022 | -60.3% | – |
| Q4 FY2020 | Dec 31, 2020 | 50.3% | – |
See a number that looks wrong?